HIV-1 coreceptor usage in paired plasma RNA and proviral DNA from patients with acute and chronic infection never treated with antiretroviral therapy

Journal of Medical Virology

Volumn 87, Issue 2, 2015, Pages 315-322

  Bon, I ^a   Turriziani, O ^b   Musumeci, G ^a   Clo A ^a   Montagna, C ^b   Morini, S ^a   Calza, L ^c   Gibellini, D ^a   Antonelli, G ^b   Re, M C ^a,d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

Author keywords

HIV new infections; Na ve; PBMCs; Plasma; Tropism

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS DNA; VIRUS RNA; VIRUS RECEPTOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYLOGENY; PREVALENCE; THERAPY; TROPISM; VIRUS LOAD; VIRUS STRAIN; CLASSIFICATION; GENETIC VARIABILITY; GENETICS; GENOTYPE; GENOTYPING TECHNIQUE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MIDDLE AGED; MONONUCLEAR CELL; PHENOTYPE; PHYSIOLOGY; PLASMA; PROVIRUS; VIRAL TROPISM; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; DNA, VIRAL; FEMALE; GENETIC VARIATION; GENOTYPE; GENOTYPING TECHNIQUES; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PHENOTYPE; PLASMA; PROVIRUSES; RECEPTORS, HIV; RNA, VIRAL; VIRAL TROPISM;

EID: 84919695089     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.24036     Document Type: Article

References (49)

1. Abbate I, Rozera G, Tommasi C, Bruselles A, Bartolini B, Chillemi G, Nicastri E, Narciso P, Ippolito G, Capobianchi MR. 2011. Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment. Clin Microbiol Infect 17:725-731.
2. Bon I, Clò A, Borderi M, Colangeli V, Calza L, Morini S, Miserocchi A, Cricca M, Gibellini D, Re MC. 2013. Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection. Int J Infect Dis 17:e875-882.
3. Brumme ZL, Goodrich J, Mayer HB, Brumme CJ, Henrick BM, Wynhoven B, Asselin JJ, Cheung PK, Hogg RS, Montaner JS, Harrigan PR. 2005. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 192:466-474.
4. Burger H, Hoover D. 2008. HIV-1 tropism, disease progression, and clinical management. J Infect Dis 198:1095-1097.
5. Bushman FD, Hoffmann C, Ronen K, Malani N, Minkah N, Rose HM, Tebas P, Wang GP. 2008. Massively parallel pyrosequencing in HIV research. AIDS 22:1411-1415.
6. Clementi M, Lazzarin A. 2010. Human immunodeficiency virus type 1 fitness and tropism: concept, quantification, and clinical relevance. Clin Microbiol Infect 16:1532-1538.
7. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. 1997. Change in coreceptor use correlates with disease progression in HIV-1- infected individuals. J Exp Med 185:621-628.
8. De Mendoza C, Rodriguez C, García F, Eiros JM, Ruíz L, Caballero E, Aguilera A, Leiva P, Colomina J, Gutierrez F, del Romero J, Aguero J, Soriano V. Spanish HIV Seroconverter Study Group. 2007. Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. J Antimicrob Chemother 59:698-704.
9. Delobel P, Sandres-Sauné K, Cazabat M, Pasquier C, Marchou B, Massip P, Izopet J. 2005. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 38:382-392.
10. Eshleman SH, Husnik M, Hudelson S, Donnell D, Huang Y, Huang W, Hart S, Jackson B, Coates T, Chesney M, Koblin B. 2007. Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection. AIDS 21:1165-1174.
11. Galàn I, Jiménez JL, González-Rivera M, De José MI, Navarro ML, Ramos JT, Mellado MJ, Gurbindo MD, Bellón JM, Resino S, Cabrero E, Muñoz-Fernández MA. 2004. Virological phenotype switches under salvage therapy with lopinavir-ritonavir in heavily pretreated HIV-1 vertically infected children. AIDS 18:247-255.
12. Gupta S, Neogi U, Srinivasa H, Shet A. 2013. High concordance of genotypic coreceptor prediction in plasma-viral RNA and proviral DNA of HIV-1 subtype C: implications for use of whole blood DNA in resource-limited settings. J Antimicrob Chemother 68:2003-2006.
13. Haqqani AA, Tilton JC. 2013. Entry inhibitors and their use in the treatment of HIV-1 infection. Antiviral Res 98:158-170.
14. Hunt PW, Harrigan PR, Huang W, Bates M, Williamson DW, McCune JM, Price RW, Spudich SS, Lampiris H, Hoh R, Leigler T, Martin JN, Deeks SG. 2006. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 194:926-930.
15. Low AJ, Dong W, Chan D, Sing T, Swanstrom R, Jensen M, Pillai S, Good B, Harrigan PR. 2007. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 21:17-24.
16. Mild M, Kvist A, Esbjörnsson J, Karlsson I, Fenyö EM, Medstrand P. 2010. Differences in molecular evolution between switch (R5 to R5 × 4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection. Infect Genet Evol 10:356-364.
17. Moreno S, Clotet B, Sarría C, Ortega E, Leal M, Rodriguez-Arrondo F, Sánchez-de la Rosa R. ALLEGRO Study Group. 2009. Prevalence of CCR5-tropic HIV- 1 among treatment-experienced individuals in Spain. HIV Clin Trials 10:394-402.
18. Mosier DE. 2009. How HIV changes its tropism: evolution and adaptation? Curr Opin HIV AIDS 4:125-130.
19. Moyle GJ, Wildfire A, Mandalia S, Mayer H, Goodrich J, Whitcomb J, Gazzard BG. 2005. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 191:866-872.
20. Noe A, Plum J, Verhofstede C. 2005. The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance. J Antimicrob Chemother 55:410-412.
21. Nozza S, Canducci F, Galli L, Cozzi-Lepri A, Capobianchi MR, Ceresola ER, Narciso P, Libertone R, Castelli P, Moioli M, D'Arminio Monforte A, Castagna A. ICONA Foundation. 2012. Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1 infected naive patients with high CD4 count. J Antimicrob Chemother 67:1224-1227.
22. Obermeier M, Symons J, Wensing AM. 2012. HIV population genotypic tropism testing and its clinical significance. Curr Opin HIV AIDS 7:470-477.
23. Paar C, Geit M, Stekel H, Berg J. 2011. Genotypic prediction of human immunodeficiency virus type 1 tropism by use of plasma and peripheral blood mononuclear cells in the routine clinical laboratory. J Clin Microbiol 49:2697-2699.
24. Parisi SG, Andreoni C, Sarmati L, Boldrin C, Buonomini AR, Andreis S, Scaggiante R, Bosco O, Manfrin V, d'Ettorre G, Mengoli C, Vullo V, Palù G, Andreoni M. 2011. HIV coreceptor tropism in paired plasma, peripheral blood mononuclear cell, and cerebrospinal fluid isolates from antiretroviral-naive subjects. J Clin Microb 49:1441-1445.
25. Poveda E, Paredes R, Moreno S, Alcamí J, Córdoba J, Delgado R, Gutiérrez F, Llibre JM, García Deltoro M, Hernández-Quero J, Pulido F, Iribarren JA, García F. 2012. Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists. AIDS Rev 14:208-217.
26. Prosperi MC, Bracciale L, Fabbiani M, Di Giambenedetto S, Razzolini F, Meini G, Colafigli M, Marzocchetti A, Cauda R, Zazzi M, De Luca A. 2010. Comparative determination of HIV-1 co-receptor tropism by enhanced sensitivity trofile, gp120 V3-loop RNA and DNA genotyping. Retrovirol; 7:56-69.
27. Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, Sandres-Sauné K, Cuzin L, Marchou B, Massip P, Izopet J. 2008. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS; 22:11-16.
28. Re MC, Schiavone P, Bon I, Vitone F, De Crignis E, Biagetti C, Gibellini D. 2010. Incomplete IgG response to HIV-1 proteins and low avidity levels in recently converted HIV patients treated with early antiretroviral therapy. Int J Infect Dis 14:1008-1012.
29. Re MC, Bon I, Grandi N, Miserocchi A, Morini S, Clo A, Furlini G, Gibellini D. 2012. Recent and long-lasting infections: the need for avidity testing in HIV-1 infected subjects. New Microbiol 35:407-414.
30. Rozera G, Abbate I, Bruselles A, Vlassi C, D'Offizi G, Narciso P, Chillemi G, Prosperi M, Ippolito G, Capobianchi MR. 2009. Archived HIV-1 minority variants detected by ultra-deep pyrosequencing in provirus may be fully replication competent. AIDS 23:2541-2543.
31. Shephard DA. 1976. The 1975 Declaration of Helsinki and consent. Can Med Assoc J; 115:1191-1192.
32. Simon B, Grabmeier-Pfistershammer K, Rieger A, Sarcletti M, Schmied B, Puchhammer-Stockl E. 2010. HIV coreceptor tropism in antiretroviral treatment-naive patients newly diagnosed at a late stage of HIV infection. AIDS 24:2051-2058.
33. Skrabal K, Trouplin V, Labrosse B, Obry V, Damond F, Hance AJ, Clavel F, Mammano F. 2003. Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations. AIDS 17:809-814.
34. Soulie C, Calvez V, Marcelin AG. 2012. Coreceptor usage in different reservoirs. Curr Opin HIV AIDS 7:450-455.
35. Spudich SS, Huang W, Nilsson AC, Petropoulos CJ, Liegler TJ, Whitcomb JM, Price RW. 2005. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J Infect Dis 191:890-889.
36. Suligoi B, Massi M, Galli C, Sciandra M, Di Sora F, Pezzotti P, Recchia O, Montella F, Sinicco A, Rezza G. 2003. Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay J Acquir Immune Defic Syndr 32:424-428.
37. Svicher V, Alteri C, Montano M, D'Arrigo R, Andreoni M, Angarano G, Antinori A, Antonelli G, Allice T, Bagnarelli P, Baldanti F, Bertoli A, Borderi M, Boeri E, Bon I, Bruzzone B, Callegaro AP, Capobianchi MR, Carosi G, Cauda R, Ceccherini-Silberstein F, Clementi M, Chirianni A, Colafigli M, D'Arminio Monforte A, De Luca A, Di Biagio A, Di Nicuolo G, Di Perri G, Di Pietro M, Di Santo F, Fabeni L, Fadda G, Galli M, Gennari W, Ghisetti V, Giacometti A, Gori C, Gori A, Gulminetti R, Leoncini F, Maffongelli G, Maggiolo F, Manca G, Gargiulo F, Martinelli C, Maserati R, Mazzotta F, Meini G, Micheli V, Monno L, Mussini C, Narciso P, Nozza S, Paolucci S, Pal G, Parisi S, Parruti G, Pignataro AR, Pollicita M, Quirino T, Re MC, Rizzardini G, Santangelo R, Scaggiante R, Sterrantino G, Turriziani O, Vatteroni ML, Vecchi L, Viscoli C, Vullo V, Zazzi M, Lazzarini A, Perno CF. DIVA group. 2012. Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. New Microbiol 35:17-25.
38. Svicher V, D'Arrigo R, Alteri C, Andreoni M, Angarano G, Antinori A, Antonelli G, Bagnarelli P, Baldanti F, Bertoli A, Borderi M, Boeri E, Bonn I, Bruzzone B, Callegaro AP, Cammarota R, Canducci F, Ceccherini-Silberstein F, Clementi M, Monforte AD, De Luca A, Di Biagio A, Di Gianbenedetto S, Di Perri G, Di Pietro M, Fabeni L, Fadda G, Galli M, Gennari W, Ghisetti V, Giacometti A, Gori A, Leoncini F, Maggiolo F, Maserati R, Mazzotta F, Micheli V, Meini G, Monno L, Mussini C, Nozza S, Paolucci S, Parisi S, Pecorari M, Pizzi D, Quirino T, Re MC, Rizzardini G, Santangelo R, Soria A, Stazi F, Sterrantino G, Turriziani O, Viscoli C, Vullo V, Lazzarin A, Perno CF. OSCAR Study Group. 2010. Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR study group. New Microbiol 33:195-206.
39. Svicher V, Alteri C, Montano M, Nori A, D'Arrigo R, Andreoni M, Angarano G, Antinori A, Antonelli G, Allice T, Bagnarelli P, Baldanti F, Bertoli A, Borderi M, Boeri E, Bon I, Bruzzone B, Barresi R, Calderisi S, Callegaro AP, Capobianchi MR, Gargiulo F, Castelli F, Cauda R, Ceccherini-Silberstein F, Clementi M, Chirianni A, Colafigli M, D'Arminio Monforte A, De Luca A, Di Biagio A, Di Nicuolo G, Di Perri G, Di Santo F, Fadda G, Galli M, Gennari W, Ghisetti V, Costantini A, Gori A, Gulminetti R, Leoncini F, Maffongelli G, Maggiolo F, Maserati R, Mazzotta F, Meini G, Micheli V, Monno L, Mussini C, Nozza S, Paolucci S, Palù G, Parisi S, Parruti G, Pignataro AR, Quirino T, Re MC, Rizzardini G, Sanguinetti M, Santangelo R, Scaggiante R, Sterrantino G, Turriziani O, Vatteroni ML, Viscoli C, Vullo V, Zazzi M, Lazzarin A, Perno CF. 2014. Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group. Infection 42:61-71.
40. Sweeting MJ, De Angelis D, Parry J, Suligoi B. 2010. Estimating the distribution of the window period for recent HIV infections: a comparison of statistical methods. Stat Med 29:3194-3202.
41. Swenson LC, Moores A, Low AJ, Thielen A, Dong W, Woods C, Jensen MA, Wynhoven B, Chan D, Glascock C, Harrigan PR. 2010. Improved detection of CXCR4- using HIV by V3 genotyping: application of population-based and 'deep' sequencing to plasma RNA and proviral DNA. J Acquir Immune Defic Syndr 54:506-510.
42. Swenson LC, Dong WW, Mo T, Demarest J, Chapman D, Ellery S, Heera J, Valdez H, Poon AF, Harrigan PR. 2013. Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing. Clin Infect Dis 56:1659-1666.
43. Turriziani O, Bucci M, Stano A, Scagnolari C, Bellomi F, Fimiani C, Mezzaroma I, D'Ettorre G, Brogi A, Vullo V, Antonelli G. 2007. Genotypic resistance of archived and circulating viral strains in the blood of treated HIV-infected individuals. J Acquir Immune Defic Syndr; 44:518-524.
44. Vandekerckhove LPR, Wensing AMJ, Kaiser R, Brun-Vézinet F, Clotet B, De Luca A, Dressler S, Garcia F, Geretti AM, Klimkait T, Korn K, Masquelier B, Perno CF, Schapiro JM, Soriano V, Sönnerborg A, Vandamme AM, Verhofstede C, Walter H, Zazzi M, Boucher CA. European Consensus Group on clinical management of tropism testing. 2011. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 11:394-407.
45. Verhofstede C, Vandekerckhove L, Eygen VV, Demecheleer E, Vandenbroucke I, Winters B, Plum J, Vogelaers D, Stuyver L. 2009. CXCR4-using HIV type 1 variants are more commonly found in peripheral blood mononuclear cell DNA than in plasma RNA. J Acquir Immune Defic Syndr 50:126-136.
46. Verhofstede C, Brudney D, Reynaerts J, Vaira D, Fransen K, De Bel A, Seguin-Devaux C, De Wit S, Vandekerckhove L, Geretti AM. 2011. Concordance between HIV-1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA. HIV Med 12:544-552.
47. Verhofstede C, Nijhuis M, Vandekerckhove L. 2012. Correlation of coreceptor usage and disease progression. Curr Opin HIV AIDS 7:432-439.
48. Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, James IT, Jenkins TM, Perros M, van der Ryst E. 2006. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 80:4909-4920.
49. Westmoreland SV, Alvarez X, deBakker C, Aye P, Wilson ML, Williams KC, Lackner AA. 2002. Developmental expression patterns of CCR5 and CXCR4 in the rhesus macaque brain. J Neuroimmunol 122:146-158.